Alcon drops 3% as Wells Fargo trims price target ahead of Q1 results
Alcon shares fell 3.02% to $73.06 as investors reacted to a fresh Wells Fargo price-target cut to $88. The drop comes ahead of Alcon’s May 6, 2026 first-quarter earnings call and with recall-related headlines still in the background.
1. What’s moving the stock
Alcon Inc. (ALC) slid about 3% in U.S. trading Wednesday (April 29, 2026) after a new analyst note lowered expectations, with Wells Fargo cutting its price target on the shares to $88. (streetinsider.com)
2. Timing: investors de-risking into near-term catalysts
The selling pressure is landing just days before a key catalyst: Alcon’s first-quarter 2026 earnings call, scheduled for May 6, 2026 at 8:00 a.m. ET. With the stock recently trading in the mid-$70s, incremental changes to outlook, margins, or procedure-demand commentary can drive outsized single-day moves into and out of the print. (investor.alcon.com)
3. Recall headline overhang remains part of the narrative
Separately, investors have been sensitive to quality and supply-chain headlines in the eye-care space. The FDA’s Custom Pak ophthalmic procedure-pack action—flagged as the most serious recall type—has highlighted risks tied to sterile-barrier integrity and potential downstream disruption for surgical settings, even though the notice describes specific affected lots. (fda.gov)
4. What to watch next
Focus is likely to center on (1) any shift in Alcon’s 2026 growth and margin trajectory on the May 6 call, (2) updates on surgical franchise momentum and product rollouts, and (3) clarity on any operational or financial impact from recall-related actions. Investors may also parse messaging ahead of the company’s AGM on April 30, 2026, including governance and the proposed cash dividend. (investor.alcon.com)